Abstract
Background Elevated lipoprotein (a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). As clinical LDL cholesterol [LDL-C] incorporates cholesterol from Lp(a) [Lp(a)-C], there is interest in quantifying the contribution of Lp(a)-C to LDL-C given implications for risk assessment, diagnosis, and treatment. Estimating Lp(a)-C is subject to inaccuracies; measuring Lp(a) particle number [Lp(a)-P] is more accurate.
Objective To capture how Lp(a) contributes to the atherogenic lipoprotein burden, we demonstrate a particle-based approach using readily available measures of Lp(a)-P and apolipoprotein B (apoB).
Methods Using the Very Large Database of Lipids (VLDbL), we compared Lp(a)-P (nmol/L) with all atherogenic particles (“non-HDL-P”). Non-HDL-P was calculated by converting apoB mass to molar concentration using the preserved molecular weight of apoB100 (512 kg/mol). We calculated the percentage of Lp(a)-P relative to non-HDL-P by Lp(a)-P deciles and stratified across sex, age, triglycerides, LDL-C, and non-HDL-C.
Results 158,260 patients from the VLDbL were included. The fraction Lp(a)-P/non-HDL-P increased with rising Lp(a)-P. Lp(a)-P comprised on average 3% of atherogenic particles among the study population and 15% at the highest Lp(a)-P decile. Findings were similar when stratified by sex. When stratified by age, Lp(a)-P/non-HDL-P was highest among the youngest and oldest patients. Lp(a)-P/non-HDL-P decreased at higher levels of triglycerides and LDL-C owing to larger contributions from VLDL and LDL.
Conclusions We demonstrate a particle-based approach to quantify the contribution of Lp(a) to total atherogenic particle burden using validated and widely available laboratory assays. Future research applying this method could define clinically meaningful thresholds and inform use in risk assessment and management.
Competing Interest Statement
Dr. Martin has research support from the American Heart Association (20SFRN35380046 and COVID19-811000), PCORI (ME-2019C1-15328), National Institutes of Health (P01 HL108800), the Aetna Foundation, the David and June Trone Family Foundation, the Pollin Digital Innovation Fund, the PJ Schafer Cardiovascular Research Fund, Sandra and Larry Small, CASCADE FH, Apple, Google, and Amgen. He has served as a consultant to Akcea, Amgen, AstraZeneca, Esperion, Kaneka, Novo Nordisk, Quest Diagnostics, Regeneron, REGENXBIO, Sanofi, and 89bio. He is a co-inventor on a system to estimate LDL cholesterol levels, patent application pending. Dr. Jones has served as an advisor to Sanofi/Regeneron. Dr. Marvel is an owner of a healthcare startup, Corrie Health.
Funding Statement
The Very Large Database of Lipids is supported by a charitable gift from the David and June Trone Family Foundation. Dr. Martin is also supported by the American Heart Association (20SFRN35380046 and COVID19-811000), PCORI (ME-2019C1-15328), and NIH (P01 HL108800).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Johns Hopkins Institutional Review Board declared this study exempt, which used de-identified data routinely collected from a commercial laboratory.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of Funding: The Very Large Database of Lipids is supported by a charitable gift from the David and June Trone Family Foundation. Dr. Martin is also supported by the American Heart Association (20SFRN35380046 and COVID19-811000), PCORI (ME-2019C1-15328), and NIH (P01 HL108800).
Disclosures: SSM has research support from the American Heart Association (20SFRN35380046 and COVID19-811000), PCORI (ME-2019C1-15328), National Institutes of Health (P01 HL108800), the Aetna Foundation, the David and June Trone Family Foundation, the Pollin Digital Innovation Fund, the PJ Schafer Cardiovascular Research Fund, Sandra and Larry Small, CASCADE FH, Apple, Google, and Amgen. He has served as a consultant to Akcea, Amgen, AstraZeneca, Esperion, Kaneka, Novo Nordisk, Quest Diagnostics, Regeneron, REGENXBIO, Sanofi, and 89bio. He is a co-inventor on a system to estimate LDL cholesterol levels, patent application pending.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.